Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Efficacy of lixisenatide in patients with type 2 diabetes : A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials

Yabe, Daisuke ; Ambos, Anu ; Cariou, Bertrand ; Duvnjak, Lea ; Evans, Marc ; González-Gálvez, Guillermo ; Lin, Jay ; Nikonova, Elena V. ; de Pablos-Velasco, Pedro and Yale, Jean François , et al. (2016) In Journal of Diabetes and its Complications 30(7). p.1385-1392
Abstract

Aims: To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). Materials and methods: In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20. μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index. Results: Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]),... (More)

Aims: To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). Materials and methods: In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20. μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index. Results: Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), -0.99 (-10.8), -0.87 (-9.5), -0.86 (-9.4), -0.83 (-9.1); and postprandial plasma glucose (PPG; mmol/L), -7.9, -5.6, -5.5, -4.3 (overall effect . P .

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Antidiabetic drug, Beta cell, GLP-1 analog, Glycemic control, Type 2 diabetes
in
Journal of Diabetes and its Complications
volume
30
issue
7
pages
1385 - 1392
publisher
Elsevier
external identifiers
  • pmid:27267268
  • wos:000382097600029
  • scopus:84971657481
ISSN
1056-8727
DOI
10.1016/j.jdiacomp.2016.05.018
language
English
LU publication?
yes
id
fe48458a-61f4-4eb3-b455-c2b1b082abc5
date added to LUP
2016-06-16 09:44:42
date last changed
2024-05-03 05:30:31
@article{fe48458a-61f4-4eb3-b455-c2b1b082abc5,
  abstract     = {{<p>Aims: To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). Materials and methods: In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20. μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index. Results: Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), -0.99 (-10.8), -0.87 (-9.5), -0.86 (-9.4), -0.83 (-9.1); and postprandial plasma glucose (PPG; mmol/L), -7.9, -5.6, -5.5, -4.3 (overall effect . P . </p>}},
  author       = {{Yabe, Daisuke and Ambos, Anu and Cariou, Bertrand and Duvnjak, Lea and Evans, Marc and González-Gálvez, Guillermo and Lin, Jay and Nikonova, Elena V. and de Pablos-Velasco, Pedro and Yale, Jean François and Ahrén, Bo}},
  issn         = {{1056-8727}},
  keywords     = {{Antidiabetic drug; Beta cell; GLP-1 analog; Glycemic control; Type 2 diabetes}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{1385--1392}},
  publisher    = {{Elsevier}},
  series       = {{Journal of Diabetes and its Complications}},
  title        = {{Efficacy of lixisenatide in patients with type 2 diabetes : A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials}},
  url          = {{http://dx.doi.org/10.1016/j.jdiacomp.2016.05.018}},
  doi          = {{10.1016/j.jdiacomp.2016.05.018}},
  volume       = {{30}},
  year         = {{2016}},
}